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Background. The World Health Organization has recommended pilot implementation of a candidate vaccine against
malaria (RTS,S/AS01) in selected sub-Saharan African countries. This exploratory study aimed to estimate the costs
of implementing RTS,S in Burkina Faso, Ghana, Kenya, Mozambique, and Tanzania. Methods. Key informants of
the expanded program on immunization at all levels in each country were interviewed on the resources required for
implementing RTS,S for routine vaccination. Unit prices were derived from the same sources or from international
price lists. Incremental costs in 2015 US dollars were aggregated per fully vaccinated child (FVC). It was assumed
the four vaccine doses were either all delivered at health facilities or the fourth dose was delivered in an outreach set-
ting. Results. The costs per FVC ranged from US$25 (Burkina Faso) to US$37 (Kenya) assuming a vaccine price of
US$5 per dose. Across countries, recurrent costs represented the largest share dominated by vaccines (including
wastage) and supply costs. Non-recurrent costs varied substantially across countries, mainly because of differences in
needs for hiring personnel, in wages, in cold-room space, and equipment. Recent vaccine introductions in the coun-
tries may have had an impact on resource availability for a new vaccine implementation. Delivering the fourth dose
in outreach settings raised the costs, mostly fuel, per FVC by less than US$1 regardless of the country. Conclusions.
This study provides relevant information for donors and decision makers about the cost of implementing RTS,S.
Variations within and across countries are important and the unknown future price per dose and wastage rate for
this candidate vaccine adds substantially to the uncertainty about the actual costs of implementation.
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Introduction
Despite an estimated 60% decrease of malaria deaths
worldwide since 2000, the latest data from the World
Health Organization (WHO) indicate that about 438,000
individuals still died of malaria in 2015.1 More than 90%
of these deaths occurred in sub-Saharan Africa, primarily
in children younger than 5 years of age. Almost all malaria-
related deaths are caused by the Plasmodium falciparum
parasite transmitted by female Anophelesmosquitos.1
Infection by P. falciparum may lead to morbidity vary-
ing from nonspecific mild febrile illness to severe or life-
threatening disease with anemia or circulatory shock,
respiratory distress, and coma. The clinical picture may
This Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
*Equal contributors.
Corresponding Author
Christophe Sauboin, GSK, Wavre, Belgium; Telephone: (32) 10 85
5111 (csauboin@yahoo.fr).
change rapidly (within 24 hours) from a seemingly mild
episode to life-threatening organ dysfunction, particularly
in young children and in adults with poor or no preexist-
ing immunity.1 As a result, the management of malaria
puts substantial pressure on the health systems of sub-
Saharan African countries.2
Intensive efforts to develop a vaccine to prevent clini-
cal malaria in young children have taken place over the
past decades with more than 30 candidate vaccines in dif-
ferent stages of evaluation.3 So far, only the RTS,S can-
didate vaccine has completed a Phase III clinical trial
program and received a positive assessment by the
European Medicines Agency.4 This vaccine is under con-
sideration for routine use in endemic countries with a
schedule potentially starting at 5 months of age. The
WHO has recommended a pilot implementation of the
RTS,S candidate vaccine in selected sub-Saharan African
countries with moderate-to-high malaria transmission
intensity, to better understand the feasibility of imple-
menting a four-dose vaccination schedule requiring addi-
tional immunization contacts, to assess the effectiveness
of the vaccine in real life settings, and to further docu-
ment the safety profile of the vaccine.1,5
The Phase III study of the RTS,S candidate vaccine
with follow-up ranging up to 4 years showed the vac-
cine’s rapidly waning immunity and moderate efficacy in
preventing clinical malaria even in the age group of chil-
dren achieving the highest degree of immunity, those
aged 5 to 17 months and receiving three doses followed
by a fourth dose about 18 months after the third.6
Nevertheless, modeling studies have suggested potential
for a substantial impact of the vaccine on the public
health burden of malaria and a likely favorable cost-
effectiveness results, although dependent on the vaccine
price, when vaccination is implemented on top of other
preventive measures such as insecticide-treated bed nets
or seasonal malaria chemoprevention in areas with para-
site prevalence above 5%.1,7,8 Furthermore, resistance
that is developing in mosquitoes to commonly used
insecticides and of the parasite to many of the available
antimalaria drugs (including emerging artemisinin resis-
tance in Southeast Asia) threaten to compromise the
effectiveness of those preventive measures.1
Ultimately, decisions about implementation of malaria
vaccination must be based on a comprehensive assess-
ment of the public health burden of the disease, the eco-
nomic value and coverage of vaccination compared with
other preventive interventions, health priorities, and the
health care system’s capacity to deliver the vaccine in its
optimal schedule.
The aim of the present study was to provide detailed
information about the incremental costs of adding malaria
vaccination to the Expanded Program on Immunization
(EPI) based on micro-costing with resource utilization data
derived from interviews with key informants of the health
care system at the country, regional, district, and health
facility levels. The study was carried out in five sub-
Saharan African countries—Burkina Faso, Ghana, Kenya,
Mozambique, and Tanzania—which may be considered as
a fair cross-section of sub-Saharan African countries in
terms of geography, malaria endemicity, and economic
development.
Methods
The main outcome of the cost analysis for introducing
the RTS,S candidate vaccine is the incremental cost of
vaccination per fully vaccinated child (FVC) in the short
term. We take the short-term perspective as this is likely
to be more appropriate for a vaccine that has received a
positive opinion from the European Medicine Agency
and is already in pilot implementation phase in three
countries (specifically Kenya, Ghana, and Malawi; two
of these countries are part of this study). Furthermore, if
recommended, the new vaccine would be added to an
existing and functioning program, the EPI, a consoli-
dated health system platform. The practical consequence
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of taking a short-term perspective is that only resources
that need to be acquired would contribute to the incre-
mental cost as opposed to spare resources. The main
classification we applied to costs is between variable and
fixed. The variable or recurrent costs depend on the
actual number of vaccine doses delivered, whereas the
fixed or non-recurrent costs include the costs of introdu-
cing the vaccination program and establishing a certain
delivery capacity, within which the costs do not depend
on the number of doses delivered.
Following the microeconomic theory of production,
both in the short-term and within the maximum produc-
tion capacity, the incremental cost is mainly influenced
by the variable rather than by the fixed cost. The contri-
bution of the fixed cost to the incremental cost is positive
when vaccine delivery requires an expansion of resources
beyond existing spare capacities of the current vaccina-
tion programs. No fixed cost is included if spare capaci-
ties cover or exceed the needs. The following formula
shows the aggregation of the fixed cost components (Cfix)
described in more detail later in the text.
Cfix =
Xn
i= 1
pi * qi  eið Þ if qi.ei
For each component to be costed i = 1, . . . , n, the unit
cost pi is multiplied by difference between the quantity
needed qi and the existing spare capacity ei. We collected
information directly on qi  eið Þ when this difference was
positive and not on the single terms of the subtraction
between qi and ei.
Vaccination Schedule
Following the design and results of the Phase III trial of
the RTS,S candidate vaccine, costs were modeled based
on administration of the recommended four doses of
vaccine. It was assumed that the first three doses could
be administered during existing routine EPI visits (e.g.,
for delivery of vitamin A supplement, growth monitor-
ing, and measles vaccination). The administration of the
fourth dose 18 months after the third dose was assumed
to require an additional visit beyond the routine EPI
window.
Data Collection
A questionnaire was prepared with the contribution of
all researchers. Several versions were prepared until
reaching an agreement on all the questions for capturing
country characteristics while maintaining comparability
across country. The questionnaire was piloted in a few
health facilities before starting the study and modified
according to the inputs from the pilot phase. In order to
reflect the heterogeneity of the incidence and burden of
malaria, several study sites for interviews with key infor-
mants were selected in different areas of each country
covering both rural and urban areas and accommodating
regions of different endemicity. Exploring areas with dif-
ferent malaria endemicity can provide important indica-
tions as endemicity levels can be good indicators of
socioeconomic and health system characteristics, with
highly endemic areas being the poorest and with the few-
est spare capacities. The informants were expert represen-
tatives of the Ministry of Health and EPI representatives
having responsibilities at the central, regional/provincial,
district, and health facility levels. A table with the list of
districts and regions included for each country is pro-
vided in the appendix (Table A1).
The interviews were, as far as possible, carried out as
face-to-face encounters at the informants’ workplace sup-
plemented by telephone contacts when a direct meeting
was not possible. The data collection process was guided
by the study questionnaire administered by a research
team in each country; informants received an inventory
of the information required prior to the interview to
allow them to prepare the data collection in advance.
The study was approved by the national institutional
review boards of each country, and interviews were only
performed after informants had signed an informed con-
sent form.
In addition to point estimates of the quantity of each
resource item required, the informants were also asked to
provide unit prices for each item. Informants were also
required to provide a plausible minimum and maximum
value allowing the researchers to include parameters
uncertainty in their estimates. In case unit prices were not
obtained from the informants of a country, unit prices
from various international organizations were applied
(Table 1). The main results are expressed in terms of the
total costs per FVC reported in 2015 US dollars (US$)
with purchasing power parities used for currency conver-
sions from the local currency to US$.9
Perspective and Scope
Costing was performed from the health care system per-
spective taking into consideration the expected costs
associated with implementation of a malaria vaccination
program. Cost estimates also included components that
could be covered by external funding, for example, non-
domestic funding sources such as GAVI (Global Alliance
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Table 1 Unit Prices for Certain Items and Assumed Useful Life for Capital Goods (US Dollars, 2015)a
Cost Item Burkina Faso Ghana Kenya Mozambique Tanzania Source
Exchange rate (local currency v. US$)–
Avg, min, max
0.0017,
0.0016,
0.0019
0.2755,
0.2387,
0.3106
0.0112,
0.0109,
0.0115
0.0319,
0.0297,
0.0333
0.0006,
0.0005,
0.0007
Oanda, historic exchange rates
Gasoline (per L) 1.18 0.98 1.15 1.27 1.13 World Bank, World
Development Indicators29
Cold room (per m2) 295 648 954 409 614 Market price
Storage volume (per m3 monthly US$) 0.89 9.70 9.54 0.99 0.020 WHO Choice
Average annual salaries
Health facility 3474 3534 2925 2554 5759 Our survey
District/region — 2602 5315 2724 6924 Our survey
National 2238 6409 12,828 3634 8662 Our survey
Unit Price Life Years
Life years, cold room — 13.6 WHO Choice
Car 17,621 7.3 WHO Choice10
Motorbike 1418.9 7.1 WHO Choice10
Cold box 144.96 5.7 WHO Choice10
Refrigerator 620.61 8.4 WHO Choice10
Shelf, cupboard 220.75 7.9 WHO Choice10
Syringes (unit) Average: 0.0873 (Min: 0.0399; Max: 0.243) UNICEF Supply Catalogue30
Safety box 0.00402 (per syringe) UNICEF Supply Catalogue30
Air freight 17.68 (per m3) UNICEF Supply Catalogue30
aIt is important to note that these are the average salaries for the professionals identified in the survey and not general average salaries. The low level of the salary at the national
level in Burkina Faso reflects the fact that, for example, it was identified that a low-level administrative profile was needed. Similarly, low-level health care workers were needed at
health facilities in Kenya.
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for Vaccines and Immunization) and other aid agencies,
in particular the vaccine acquisition costs. The study did
not distinguish between economic and financial costs.
Most of estimated costs may express a potential financial
disburse for the national health system, such as the pur-
chase of the vaccines as well as all the incremental
resources needed. Certain costs are likely to be nonfinan-
cial opportunity costs, such as the extra time required
from workers already operating for the EPI without hir-
ing extra worker.
Cost Components
The main items in the cost estimations included the pur-
chase prices of the vaccine and vaccine supplies (syringes,
cotton, alcohol, and safety boxes), wastage, cold chain
storage/distribution, administration of the vaccine, man-
agement, training, and social mobilization. These ele-
ments are further detailed below.
Purchases. The purchase costs for the vaccine included
freight to the country and wastage. Wastage was a com-
posite variable, including the following: 1) vaccine loss
along the line of cold chain supply/distribution/storage
due, for example, to inadequate control of the tempera-
ture range and damage; 2) vaccine wastage during recon-
stitution; 3) vaccine wastage in dose administration (e.g.,
if both doses of a reconstituted vial were not adminis-
tered within the allowed time window). The informants
were asked to use the EPI vaccine most similar to the
malaria candidate vaccine (e.g., other needle-based vac-
cines requiring reconstruction, such as yellow fever vac-
cine when included in routine EPI of endemic countries)
for estimating this loss/waste and to provide separate
estimates for each of the components mentioned. The
total wastage was calculated on the assumption that the
informants reported their estimate of the average total
waste from the central storehouse to the point of vacci-
nation delivery.
Costs were calculated based on different assumptions
for the price per vaccine dose: US$2, US$5, and US$10.
The detailed cost estimates are only presented for the
mid-price of US$5, for simplicity and as other cost items
than vaccine purchase do not depend on the assumed
vaccine price.
Distribution (Cold Chain). For the estimation of cold
space requirements and the costs of vaccine delivery, the
costing scenario was based on an injectable vaccine with
the physical characteristics of the RTS,S candidate
vaccine: a lyophilized vaccine to be injected after recon-
stitution with a liquid adjuvant, each requiring cold stor-
age at 2C to 8C. The two-vial package including the
vaccine and adjuvant had a volume of 9.7 cm3 and con-
tained two vaccine doses after reconstitution.
Distribution included transportation and cold chain
costs. Informants were asked to indicate the frequency of
distribution of vaccines from the central distribution
point to the peripheral levels and how this frequency was
determined. Transportation included recurrent costs
(mainly fuel, driver costs, and maintenance) from the
central distribution point to subsequent storage points
and from these to the peripheral health facilities. The
main components of cold chain costs related to cold
boxes, vaccine carriers, space required for cold storage
of the malaria vaccine, and the amount of spare capacity
available.
Storage (Cold Chain). Storage consisted of capital costs
of cold rooms and associated recurrent costs to power
them. Costs were split between the central, regional, and
local (peripheral) levels. The unit prices were derived
from the replacement value of a cold room annualized
over its assumed length of useful life (WHO-Choice; see
Table 1).10 The quantity was the estimated share of cold
room volume and surface required for storage of the vac-
cine doses at the different levels depending on the average
storage period at each level. To determine the economic
costs, the informants were asked to evaluate the current
level of capacity utilization and the possible need for
additional capacity to accommodate for the malaria vac-
cination implementation.
Management. Implementation of malaria vaccination
will require additional management resources at all levels
for monitoring, evaluation, and quality control. Informants
were asked to estimate the amount of time dedicated to one
single type of vaccine required for the managers involved
and the anticipated need for hiring additional managers.
The cost related to these additional resources were conser-
vatively fully allocated to RTS,S.
Vaccine Administration. At the health facility level, the
administration of the vaccine involved various types of
resources such as consumables (vaccine supplies such as
syringes, safety boxes, disinfectants, cotton pads, and
recording tools), personnel, and capital costs for waste
management. Personnel time was assessed as the esti-
mated time required for preparation and administration
of one vaccine dose. The costing of personnel time was
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based on estimates of the extent to which the vaccine
would be administered by different categories of person-
nel (physicians, nurses, other health care assistants). The
time needed for administering a vaccine with similar
characteristics to the RTS,S malaria vaccine candidate
was self-reported by the interviewees. Self-reported dura-
tions were averaged per vaccine type across health facili-
ties and then averaged across health facilities within each
country.
Two different scenarios were considered: 1) adminis-
tration of all doses of the vaccine at the health facility
and 2) administration of the first three doses at the health
facility and the fourth in an existing outreach setting.
Compared to administration at the health facility, the
outreach setting required additional resources for trans-
portation, cold chain distribution, and storage space
where the vaccine administration would take place.
Outreach vaccination was quite common in the selected
country areas, except for the areas in Tanzania, where
this mode of vaccination is rarely practiced, and then
only considered as a part of community sensitization. As
such, the cost calculation for Tanzania was limited to the
scenario with delivery of all four doses at the health
facility.
Training. For each training session organized for the
introduction of the malaria vaccine, the estimated costs
comprised the renting of space, daily allowance for the
trainees, remuneration of the trainers, accommodation,
food, and traveling costs for all. Informants were asked
to base their estimates on experiences from the most
recent addition of vaccines to the EPI.
Social Mobilization. Costs associated with social mobili-
zation campaigns included transportation, per diems for
people contributing to the campaign and the costs of
materials prepared and used in the campaign (such as T-
shirts, leaflets, radio/TV communications). As for train-
ing, the informants were asked to base their assessment
on the experience acquired during the mobilization cam-
paign for recent additions of vaccines to the EPI, noting
if these were organized centrally or locally, who partici-
pated in these activities, and over what period of time.
Allocation of Non-Recurrent (Fixed) Costs per
FVC
For the calculation of the cost per FVC, non-recurrent
(fixed) costs exceeding the existing spare capacities (Cfix)
at each level (national, regional, district, health facility)
were allocated among all the children potentially vacci-
nated (= the target group) during the next N years. Cfix
at each level were sensitization, training, supply chain,
and personnel. Vaccine-specific training and social mobi-
lization were assumed to have an effect lasting for 10
years.11 Therefore, sensitization and training costs were
divided by the projected number of children in the target
group over 10 years. The number of years considered per
type of resource other than training and social mobiliza-
tion depended on its assumed years of useful life (Table
1).10 Therefore, costs from supply chain items and per-
sonnel were divided by 1 year of projected number of
target children as such costs were annualized based on
the years of useful life (the former) or on the yearly sal-
ary (the latter).
At the national level, the number of potentially vacci-
nated children was estimated based on the United
Nations’ demographic projections (medium variant fore-
cast).12 The number of births per year in a country was
diminished by half of the corresponding infant mortality
rate under the assumption that half of the infants who
died during the first year of life would not receive any
malaria vaccine dose.
At the regional and district levels, the number of chil-
dren potentially vaccinated was based on the most recent
national census data,13–17 with the total population of all
ages updated to 2015 based on the country-specific popu-
lation growth rate. The number of births for every region/
district included in the study was estimated assuming that
the proportion of births relative to the total population
and the infant mortality rate at the region and district
level were the same as at the national level.
At the health facility level, the number of potentially
vaccinated children was based on the catchment popula-
tion of the health facility assuming that the size of the birth
cohort each year remains the same from 2015 to 2025.
This information was collected as part of the question-
naire. Information on the estimated number of children to
be vaccinated is reported in the appendix (Table A3).
The outcome of this analysis was the incremental fixed
cost per child in the target group (= per child potentially
vaccinated).
Calculation of the Recurrent (Variable) Costs
per FVC
Recurrent costs were related to personnel time for vac-
cine administration, supplies, transportation, vaccine
purchase, and wastage. In each country, all variable cost
components were calculated as the average of reported
figures across the health facilities included in the study.
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Importantly, personnel cost at the health facility level
was included even in the case that no additional staff
was expected to be hired in order to account for the
additional pressure on the EPI staff and to highlight the
potential investment needs for the malaria vaccine intro-
duction. Staff time employed in vaccine administration
depends on the number of doses being administered;
thus, it was considered as a variable cost.
Calculation of the Incremental Costs per FVC
For each country, the marginal cost per FVC was given
by the sum of the fixed cost per child in the target group
and the variable cost associated with four doses each of
these children should receive. All levels (national, regional/
province, district, and health facility) were aggregated in
this estimate.
As a summary:
Costfvc=Fixed cost per child +Variable cost for 4 doses
Fixed cost per child
=
FC at national level
N estimated target children at national level
+
FC at regional=province level
N estimated target children at regional=province level
+
FC at district level
N estimated target children at district level
+ 0:8
 FC at health facility level
N estimated target children in the HF catchment population
Due to the multilevel nature of the data and the likeli-
hood of correlated costs across the various levels, the cal-
culation was based on the assumption that only 80% of
the non-recurrent costs incurred at the health facility
level contributed to the total costs. Therefore, a
‘‘between-levels adjustment’’ equal to a 20% reduction in
fixed costs at the health facility level was applied. In
other words, the estimated total fixed cost per FVC is
not the sum of the average fixed costs across levels
(national, subnational, and health facility levels) because
there were potential risks of ‘‘double counting’’ when
summing up fixed costs across all levels. Double count-
ing may occur more specifically at the health facility
level. For example, several health facilities from the same
district may report the need for a new motorbike for vac-
cination outreach but this new resource would actually
be shared across these facilities and managed directly at
the district level. The between-levels adjustment therefore
represents potential economies of scope.
Variable costs per FVC
= Personnel cost for administration of 1 dose½
+Air freight per dose+Vaccine cost per dose
+(Vaccine wastage at national level
+Vaccine wastage at regional level
+Vaccine wastage at the district level
+Vaccine wastage at the HF level)
= number of levelsð Þ  4 doses
Personnel cost of administering one dose represents the
opportunity cost of time of already employed EPI per-
sonnel at the facility level, which is likely to be nonfinan-
cial considering that that the extra work is performed by
current workers and no extra worker is hired.
Airfreight costs, expressed per m3 (Table 1), were divided
by the volume of each RTS,S dose. Vaccine wastage was
valued at the dose price. The average wastage rate across
levels was taken in order to avoid double counting.
In the scenario with the fourth dose delivered in an
outreach manner, the personnel and transportation costs
associated were added; the latter consisting of personnel
time to reach the communities and fuel required.
The total incremental costs per FVC were calculated
by summing up the fixed costs at each level allocated to
each potentially vaccinated child and adding the variable
costs including the costs of the vaccine doses and supplies.
All the fixed costs were discounted at 3% per annum.
In addition, each cost was estimated with an average,
a minimum, and a maximum value. This was possible as
interviewees were asked to report a range of plausible
value for each resource needed.
Importantly, this study is exploratory of the cost of
introduction of RTS,S in malaria endemic countries of
sub-Saharan Africa. Our sample of countries, provinces/
districts, and health facilities has been determined with
the aim of representing as much as possible variations
over a number of dimensions (level and characteristics of
endemicity, wealth, and level of urbanization).
Results
A total of 59 interviews were carried out over the first
semester of 2015. Table A1 reports where interviews were
undertaken. Table A2 reports a summary of reported
resources needed at the national level and the average of
the resources reported as needed at lower levels.
A breakdown of the incremental cost estimates per
FVC assuming a vaccine price per dose of US$5 is pre-
sented in Table 2. The lowest costs per FVC were found
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Table 2 Distribution by Activity and Items of Incremental Economic Cost per Fully Vaccinated Child (US Dollars, 2015)a
Cost Items
Burkina Faso Ghana Kenya Mozambique Tanzania
SD Among
US$ Cost
Items
CV
US$
Cost Items
Ranking of
Variation Based on
CV (1 = Highest
Variation)US$
% of
Subtotal US$
% of
Subtotal US$
% of
Subtotal US$
% of
Subtotal US$
% of
Subtotal
Non-recurrent costs
Cold room space/equipment 0.28 14.5 0.38 23.3 0.91 4.9 0.51 14.7 2.52 53.1 0.93 1.21 3
Training 0.15 8.1 0.51 31.3 0.62 3.3 0.15 4.2 0.27 5.7 0.21 0.75 5
Social mobilization 0.14 7.1 0.30 18.6 0.23 0.91 0.10 2.9 0.00 \ 0.1 0.12 0.90 4
Human resource 1.73 89.4 0.60 37.1 14.14 75.8 3.13 90.7 3.08 64.9 5.47 1.45 1
Adjustment between levels 0.36 18.9 0.17 10.3 2.75 14.7 0.43 12.5 1.12 23.7
Subtotal 1.93 100 1.62 100 18.65 100 3.46 100 4.74 100
Recurrent costs, vaccine-related
Vaccine 20.00 89.4 20.00 85.4 20.00 88.8 20.00 92.3 20.00 88.2 0 0 —
Vaccine wastage 2.36 10.6 3.43 14.6 2.53 11.2 1.70 7.7 2.68 11.8 0.62 0.29 9
Air freight 0.00 — 0.00 — 0.00 — 0.00 — 0.00 — 0 0 —
Subtotal 22.36 100 23.43 100 22.53 100 21.70 100 22.68 100
Recurrent costs, Scenario 1b
Labor 0.04 6.1 0.10 12.7 0.08 11.9 0.08 8.1 0.19 17.6 0.06 0.68 6
Supplies 0.61 93.9 0.69 87.3 0.60 88.1 0.97 91.9 0.90 82.4 0.17 0.27 10
Subtotal 0.64 100 0.79 100 0.68 100 1.05 100 1.09 100 0.21 0.29 8
Recurrent costs, Scenario 2
c
Labor 0.16 19.3 0.32 22.1 0.19 23.9 0.29 21.2 — — 0.08 0.32 7
Supplies 0.61 7.9 0.69 46.9 0.60 75 0.97 70.6 — — 0.17 0.24 11
Fuel 0.07 72.8 0.47 31.7 0.01 1.1 0.11 8.2 — — 0.21 1.26 2
Subtotal 0.83 100 1.48 100 0.80 100 1.37 100 — —
Total costs, Scenario 1 24.93 25.84 36.35 26.21 28.51
Total costs, Scenario 2 25.12 26.53 36.48 26.53 —
CV, coefficient of variation is given by SD/mean across countries for each cost item: it is also called stan; SD, standard deviation.
aAdjustment between levels, that is, it was assumed that only 80% of the calculated costs for the health facilities were part of the actual total costs, so the amount indicated in the
adjustment row is deducted from the other rows to arrive at total costs. Vaccine price per dose is assumed at US$5.
bScenario 1: Four doses administered at health facilities.
cScenario 2: Three doses administered at health facilities, 1 as outreach. Scenario 2 was not calculated for Tanzania as vaccinations are not administered in outreach settings.
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for Burkina Faso with all four doses delivered at health
facilities. The highest costs per FVC were found for
Kenya, 46% higher than those in Burkina Faso. Only
the mean incremental values are presented in the table
because for all the cost items except those related to the
vaccine (including wastage), the range between minimum
and maximum was less than US$1.
The non-recurrent costs related to the introduction of
the new vaccine made up a highly variable proportion of
the marginal costs per FVC, ranging from 7% in Ghana
to 37% in Kenya. In absolute terms, the non-recurrent
costs were eight times higher in Kenya than in Ghana. At
least in part, this discrepancy was due to the far higher
salaries at the national level in Kenya than in Ghana and
the fact that each health facility in Kenya reported a need
to hire more personnel whereas the facilities in Ghana
basically did not report any need for additional person-
nel. In total, the non-recurrent human resources costs
related to implementation were 23 times higher in Kenya
than in Ghana.
The recurrent costs were entirely dominated by the
vaccine costs (including wastage), which were very simi-
lar across the countries and made up 93% to 97%. The
estimated wastage rates were similar in Burkina Faso,
Kenya, and Tanzania (10% to 11%), whereas the
wastage rates were higher in Ghana (14.1%) and lower
in Mozambique (7.3%).
Overall, the cost item presenting the highest variation
across country was, among non-recurrent costs, human
resources, with the highest standard deviation (SD; 5.47)
and coefficient of variation (CV; 1.45). Among non-
recurrent costs, the second cost item presenting the high-
est variation across country was cold room space/equip-
ment (CV = 1.21). A high level of variation (CV = 1.26)
was in fuel costs, item included in recurrent costs, out-
reach scenario.
In all the four countries with existing outreach vacci-
nation settings, the costs of delivering all four doses in
the health facility were lower than the costs of delivering
the first three doses in the health facility and the last dose
in the outreach setting, but the difference was marginal,
ranging from US$0.11 to US$0.69 per FVC. Table A5 in
the appendix provides additional details on outreach
travel time reported.
Table 3 presents the spread of the mean total costs
per FVC when the price of a vaccine dose is varied.
Appendix Table A4 shows the detailed cost items, when
all costs are presented at their minimum and maximum
estimate. Additional information on time estimated for
vaccine reconstitution and administration is provided in
Appendix Table A5.
The distribution of the non-recurrent costs of introdu-
cing the new vaccine across the various administrative
levels varied quite considerably between countries with
regard to the district and health facility levels, whereas
the costs at the national and regional levels were low in
all the countries, both in an absolute and relative sense
(Table 4). In Ghana and Mozambique, the proportion of
non-recurrent costs incurred at the district level was
much higher than in any of the other three countries.
Discussion
The estimated costs per FVC were rather similar across
the countries with Kenya as an outlier because of very
high introduction costs mainly due to the need to hire
additional personnel and relatively high salaries com-
pared with the other countries. Comparatively high
introduction costs were also responsible for Tanzania’s
position with costs per FVC in-between Kenya and the
other three countries. Recurrent costs were similar across
countries and in all countries delivering the fourth dose
in an existing outreach setting was only slightly costlier
than delivering all four doses in health facilities. Non-
recurrent cost variations across countries mirrored the
different situations in terms of resources needed on top
of available resources. Some countries were fully using
their capacities when, for example, after a recent and
efficient vaccine introduction, whereas other countries
have large spare resources. For example, all the countries
studied had recently introduced a Rotavirus vaccine.
Table 3 Economic Costs (in 2015 US Dollars) per Fully Vaccinated Child Varying the Vaccine Price Between US$2, US$5, and
US$10a
Vaccine Price Burkina Faso Ghana Kenya Mozambique Tanzania
US$2 11.52 11.78 22.83 13.19 14.90
US$5 24.93 25.84 36.35 26.21 28.51
US$10 43.40 47.36 57.23 43.15 47.67
aAssuming all four doses administered at health facilities.
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However, the variation in the introduction year likely
affected our estimates (Ghana and Tanzania introduced
it in 2012, Burkina Faso in 2013, Kenya in 2014, and
lastly Mozambique in 2015).18 Therefore, our estimates
would reflect, to a certain extent, the vaccine manage-
ment in different settings as well as the recent decisions
on introducing additional vaccines (or not) to the EPI.
We employed an incremental cost analysis in the pres-
ent study that includes the additional fixed costs based
on new resources needed beyond the spare capacity in
the health system. We took this approach as we consider
that the information obtained is easily interpretable and
most relevant for decision makers in resource allocation
decisions. Additionally, in the short term, incremental
costs are given by variable rather than by fixed produc-
tion inputs within the existing maximum production
capacity.19 Within the context of our study, this means
that, where no additional fixed cost is incurred (e.g., no
new fridges are needed), the incremental cost of the
malaria vaccine is given by the variable cost of the vac-
cine only (e.g., by the cost of the vials). On the contrary,
when fixed costs are incurred (e.g., a new fridge is
needed) these contribute to the marginal cost and are,
therefore, factored in our estimates.
We defined our costs as incremental. However, we
could have interpreted costs as marginal by applying the
idea that a new vaccination program represents ‘‘the next
logical batch of output.’’20 As our study involved the
resources needed for an additional vaccination program
added to EPI and not for an additional quantity of out-
put produced, our estimated costs are more incremental
rather than marginal. However, as the new vaccination
program relies on an already existing platform of pro-
duction of the same type of service, vaccination, in the
short term, fixed costs still play a role only if these go
beyond the maximum current EPI delivery capacity;
variable costs, instead, always play a role.
We did not report the cost per dose of vaccine admi-
nistered, because the non-recurrent costs per FVC were
calculated by dividing the total non-recurrent costs by
the total number of potentially vaccinated children
expected over the time horizon of the calculation for the
associated resource. In practice, complete vaccination
coverage may probably not be attained, particularly dur-
ing the first years following implementation and the cost
per dose administered depends on the assumed vaccina-
tion coverage. For comparison with other studies, a sim-
ple approximation may be applied by deducting the
vaccine purchase cost of US$20 for four doses from the
estimated costs per FVC and dividing by four. The
approximate costs for administering one dose obtained
by this calculation ranged between US$1.28 in Burkina
Faso and US$4.12 in Kenya (considering the possibility
of the dose delivered in an outreach manner and includ-
ing wastage) or between US$0.64 and US$3.45 with
delivery at the health facility and excluding wastage. We
compared the recurrent costs per dose delivered with the
delivery costs estimated in other studies on new vaccines
(HPV vaccine specifically).21 Our delivery cost per dose
ranged from US$0.16 in Burkina Faso to US$0.27 in
Mozambique and from US$0.2 in Kenya to US$0.37 in
Ghana, considering health facility or outreach delivery,
respectively. Our estimates are similar to the estimates of
the cited study although higher for health facility–based
administration and lower for the outreach administra-
tion (0.09 and 0.57 in 2014 US$).21 The comparison is
difficult for the different approach used (full cost v.
incremental in our case) and for the different sample
included: Botwright et al21 included 12 countries across
continents. In addition, Botwright et al. measured costs
as part of implementation (demonstration) projects.
Their costs will be more easily compared to those cur-
rently measured during implementation of RTS,S in
selected countries.22
Table 4 Non-Recurrent Incremental Economic Costs per Fully Vaccinated Child at Different Levels of New Vaccine
Implementation (2015 US Dollars)
Level
Burkina Faso Ghana Kenya Mozambique Tanzania
US$ % US$ % US$ % US$ % US$ %
National 0.12 6.1 0.08 5.2 0.04 0.3 0.04 1.3 0.02 0.4
Regional 0.05 2.5 0.17 10.4 0.01 0.2 0.07 1.5
District 0.30 15.7 0.70 43.3 2.11 16.4 1.68 48.6 0.17 3.4
Facility (adjusted)a 1.47 75.7 0.67 41.1 10.99 83.6 1.73 50.0 4.50 94.6
Total 1.94 100 1.62 100 13.13 100 3.45 100 4.75 100
aAdjustment between levels, that is, it was assumed that only 80% of the calculated costs for the health facilities were part of the actual total
costs, so the amount indicated in the adjustment row is deducted from the other rows to arrive at total costs.
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In another recent study, Galactionova and colleagues
estimated the costs of implementing the malaria vaccine in
six sub-Saharan countries based on secondary, routinely
collected, and publicly available data.23 Four of the coun-
tries examined were the same as in our study and assuming
a vaccine price of US$5 per dose, their estimated total eco-
nomic costs per FVC with four doses delivered by the same
schedule as used in our study ranged from US$36.25 in
Burkina Faso to US$44.49 in Kenya. Despite the different
approaches to data collection, the estimated total costs per
FVC were rather similar to ours but their estimates of the
introduction costs were much lower, in particular for
Kenya with US$1.58 in financial costs per surviving infant.
There is, however, a major difference between that study
and ours, because Galactionova et al. estimated the finan-
cial costs under an assumption of 100% spare capacity to
accommodate the vaccine. However, as it is recognized
that some countries may need to invest in scaling-up across
a range of service inputs, assumptions for capacity scale-
up are presented. While the financial costs are based on
the assumption of 100% spare capacity, the economic
costs are implicitly evaluated under the assumption of no
spare capacity. In this study, only the estimated resources
beyond the existing capacities are included (incremental
costs). Another difference was that they estimated that vac-
cines and supplies made up 84% of the recurrent economic
costs, whereas our estimates for these were in the range
93% to 97%. This difference may be due to lower recur-
rent costs per FVC in our study related to our assumption
of full coverage as explained in the following paragraph. A
further difference is the exclusion in our study of postintro-
duction monitoring costs, including those for vaccine
safety. These costs were estimated in Galactionova et al. as
2% to 13% of the annual economic cost (depending on
the country). The exclusion of these costs is certainly a lim-
itation in our study, although we do not expect this to have
a strong impact on the final cost due to the implementa-
tion piloting of RTS,S currently in place in Ghana, Kenya,
and Malawi, where the safety profile of the candidate vac-
cine is under evaluation.24
A previous study estimated the cost of introduction of
a malaria vaccine (not specific to RTS,S characteristics
at that time) through the EPI in Tanzania.25 That study
assumed three vaccine doses and reported both average
(including spare capacities) and marginal costs.
Expressed in 2005 US$, their cost estimate for the mar-
ginal FVC was just below US$30 at a vaccine price of
US$10 per dose. Our estimate for Tanzania at US$10
per dose is just below US$48 (four doses, 2015 US$).
As usual, comparisons are difficult to make between
cost studies. However, we can speculate that given that
the activities considered for cost estimates are very sim-
ilar, the estimates from the two studies are not too dif-
ferent: Hutton et al. estimated that the cost for four
doses at US$10 would be approximately US$42.5 in
2015 US$.17
When comparing our cost estimates with those of
other relevant studies, we could not directly validate our
results against some with other approaches such as, for
example, the content of comprehensive multi-year plan
(cMYP) for immunization. This is due to the fact that
cMYPs have different perspectives from our study:
cMYPs take a macroeconomic (national) and financial
perspective; our study takes the microeconomic perspec-
tive and our estimates are economic, not nationally rep-
resentative and incremental. However, cMYPs may have
influenced the data we collected and the replies of our
interviewees, particularly at the national level, where
informants took much information from vaccination
documents including the cMYP.
For the calculation of the total costs per FVC, we
assumed complete coverage of the malaria vaccination
for the anticipated birth cohorts as an estimate of the
number of children the non-recurrent introduction costs
should be divided by. In other words, we divided the
non-recurrent (fixed) costs among all the projected num-
ber of children that theoretically could be vaccinated.
This is a logical assumption given that the setup of a new
vaccination program should guarantee the service to the
entire eligible population. Therefore, we consider that
the fixed incremental costs should be divided among the
whole projected target population instead of just a part
of it as the aim should be to cover the whole eligible pop-
ulation. Given the weight of the vaccine purchase in the
non-recurrent costs, assuming lower and probably more
realistic coverage rates of 60% to 70% would only mar-
ginally change the introduction costs per FVC. However,
as all the children receiving between one and three vac-
cine doses would incur costs for the vaccines, but not be
accounted for in the denominator (total number of
FVCs), the lower coverage could have a considerable
impact on the cost per FVC.
The wastage rate is generally an essential factor that
may vary greatly, partly depending on the vaccine pre-
sentation. Around the year 2000, wastage rates ranging
from 3% to 51% were reported,26 and they may not
have improved by much since then, as more recent data
indicate rates of 5% for rotavirus and pneumococcal
vaccines but 40% for measles vaccine.27 Our estimates
ranging from 8% to 17% are relatively low but realistic.
Before the introduction of the vaccination in routine
practice this rate cannot be assessed.
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Compared with using secondary data, primary data
collection for facility-based costing data collection has
the potential to better capture the costs of vaccination
through more detailed analysis of the resources involved.
However, cost studies at the facility level are costly to
undertake and it is important to consider the balance
between feasibility and generalizability, as there are also
data indicating that within-country differences in costs at
the facility level may be substantial. In Uganda, for
example, facility-level costs were found to vary by a fac-
tor of 60.27
We aimed to investigate a sample of health facilities in
different settings in each country but the results can only
be interpreted as indicative for other settings. Our study
was exploratory in character, and to obtain more defini-
tive results much larger samples should be investigated as
recommended by a costing guide prepared for the Gates
Foundation.28 This is a limitation of this study. Also,
while we present, for convenience, our results as ‘‘per
country,’’ in reality our results reflect an average across
‘‘more local’’ situations: for example, we did not include
outreach costs for Tanzania as no outreach is done in the
settings we evaluated, which may not necessarily apply
to the whole country.
Using interviews and questionnaires for data collec-
tion and not actual time-and-motion studies or other
methods for measurement of resources needed may lead
to bias due to strategic answers by those informants
intending to favor implementation of the new vaccine.26
The need for increasing the capacity of the cold chain
may have been underestimated for this reason in order
to improve the chances of having the new vaccine imple-
mented in the EPI. In the event that this type of bias
occurred in our study, both the introduction costs and
the recurrent costs have been underestimated because the
wastage would become higher in practice than antici-
pated. Arguably, an opposite bias would also be possi-
ble, if respondents inflate the requirement of additional
resources in order to obtain a higher vaccine introduc-
tion grant or more resources allocated to different levels.
Again, it is a question of balancing feasibility and the
much higher costs of collecting possibly more accurate
data. Whether and to what extent such hypothetical bias
occurred in our study is difficult to judge or estimate.
This study showed that even though vaccine purchase
including wastage make up about 95% of the recurrent
costs per FVC, other incremental economic costs associ-
ated with implementation of a new vaccine like the
RTS,S candidate vaccine are not negligible. Our costing
approach aimed at estimating the incremental economic
costs associated with the implementation of the RTS,S
candidate vaccine allowing for spare capacity to be used
without adding to the costs as would be the case if esti-
mating the full opportunity costs of implementation.
Excluding the vaccine purchase, the incremental eco-
nomic costs estimated this way amounted to between
US$4.93 and US$16.35 per FVC dependent on the
amount of spare capacity and wage levels of the coun-
tries investigated. These costs are substantial (between
25% and 85% of the vaccine purchase cost at an inter-
mediate vaccine price of US$5 per dose) and should be
taken into account in implementation decisions.
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